A pair of lawmakers wants the US Food and Drug Administration to explain its rationale for approving a decades-old drug to treat a rare disease that has caused controversy after the manufacturer, Marathon Pharmaceuticals, set a surprisingly high price of $89,000 a year.

In particular, the lawmakers are upset that the agency extended two coveted prizes — orphan drug designation and a priority review voucher —that provide Marathon with seven years of marketing exclusivity and, potentially, extra cash even though the company did not invent the drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • While I respect the Senator’s right to quote ‘more effective, safe and more affordable,’ I have heard FDA say that the price/ economic factors around a drug are not within their purview to review. As I know the FD&C Act, the criteria are ‘Pure, Safe and Effective.’ The economic$ are not included.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy